Biyinlefen: net profit increased by 45% - 55% in the first half of the year

Unpacking Japanese E-commerce：The Overlooked 120 Million Consumers

Japan is a demanding but high-value market. Chinese sellers are growing fast, yet success requires more than low prices—clear manuals, strong quality, 24/7 service, and trust. Consumption is polarizing, and aging buyers remain active. Long-term branding and localization are key.

Blokees’ Overseas Revenue Surges 228.5% as Building Toys Gain Global Traction

Chinese building-toy company Blokees (布鲁可) reported on Aug. 12 that its overseas revenue reached CNY 366 million in the first half of 2026, up 228.5% year on year, as the company expanded its distribution and licensed-IP product portfolio across the Americas and Southeast Asia.

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.

Temu Expands Slovenian Seller Network as EU Tightens Cross-Border E-Commerce Rules

Temu（拼多多海外电商平台）, the cross-border marketplace backed by PDD Holdings（拼多多控股）, is expanding its local-seller and logistics footprint in Slovenia, positioning itself for a European market where low-value imports face new customs costs and online marketplaces face tougher accountability rules.

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.